A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438, 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Vonoprazan (Primary) ; Lansoprazole
- Indications Erosive oesophagitis
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 31 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2018.
- 27 Apr 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 25 Mar 2015 New trial record